Accelerating Research with Autonomous Agents

Phylo and Chugai Partner for AI Drug Discovery

Collaboration integrates Biomni Lab agentic AI platform to streamline data and treatment testing.

By Kronos Digital News Desk··1 min read
A digital display in a laboratory showing 3D protein structures and complex data analysis for drug discovery.

A digital display in a laboratory showing 3D protein structures and complex data analysis for drug discovery.

Photo: Kronos Digital News

Phylo, Inc. and Chugai Pharmaceutical have partnered to integrate the Biomni Lab platform into drug discovery [1]. This agentic AI system aims to consolidate fragmented biomedical datasets [1][3]. It uses autonomous AI agents to hypothesize and test new treatments more efficiently than traditional methods [1][2].

The platform helps researchers navigate complex data to identify potential therapeutic candidates [2]. By automating various stages of the workflow, the companies expect to accelerate the development of new medicines [3]. Chugai is deploying these agents across its drug discovery operations [3].

Editorial notes

Transparency note

AI assisted drafting. Human edited and reviewed.

AI assisted
Yes
Human review
Yes
Last updated

Risk assessment

Low

Reviewed for sourcing quality and editorial consistency.

Sources

Related stories

View all

Topics

Get the weekly briefing

A concise briefing with selected stories and analysis.

No spam. Unsubscribe anytime. By joining, you agree to our Privacy Policy.

About the author

Kronos Digital News Desk covers accelerating research with autonomous agents and editorial analysis for Kronos Digital News.